Shanghai Cellular Therapy Group and Baoren Life Insurance Forge Strategic Partnership to Pioneer Innovative Cell Therapy-Insurance Integration Model

Recently, Haier Capital's co-creation partner in the medical and health sector — Shanghai Cell Therapy Group Co., Ltd. — officially signed a strategic cooperation agreement with Aeon Life Insurance Company Limited, marking the beginning of their joint exploration into an innovative model that combines cell therapy with insurance services.

Qian Qijun, Chairman and CEO of Shanghai Cell Therapy Group, Xiang Kexin, Vice President of the Group and President of Cell Health, Zhang Ting, Senior Director of Institutional Business Department, Dai Wenhao, Deputy Secretary of the Party Committee and President of Aeon Life Insurance Company Limited, Feng Jintao, proposed Vice President of Aeon Life, Zhang Hui, Chief Actuary of Aeon Life, Guo Feng, General Manager of Aicube, and other leaders attended the signing ceremony.

Shanghai Cell Therapy Group, as the first and only innovative company in China covering the entire value chain of cell healthcare, has been focusing on the in-depth development of cell technology for many years. It boasts an elite team composed of top scientific research talents and professional medical teams from both within and outside China. The group is committed to driving innovation through science and technology, achieving a series of remarkable accomplishments in the research and development, clinical application, and industrialization of cell therapy technologies.

By exploring breakthroughs in underlying technologies, the group has successfully built a low-cost, short-cycle Flash CAR-T cell preparation platform, significantly reducing the cell preparation cycle and treatment costs while maintaining high drug value. This innovative model not only addresses the accessibility challenges of cell therapy but also establishes a complete industrial ecosystem loop from cell storage to cell drug development, clinical treatment, and health management.

Aeon Life Insurance Company Limited, as a leader in the insurance industry, always takes customer needs as the guide, adheres to being customer-centric, and is driven by professionalism and value, providing customers with comprehensive health security services. The company has an extensive market network across China, forming a service ecosystem that covers the entire life cycle of customers.

Through this collaboration, both parties will fully leverage their respective strengths to provide customers with more comprehensive and personalized health solutions, promote the popularization and development of cell therapy technology, and bring hope and health to more patients.

At the signing ceremony, Professor Qijun Qian stated: "This strategic cooperation marks an important step for both parties in the fields of health management and insurance coverage. Through this collaboration, we will jointly promote the deep integration of cell therapy and insurance services, providing customers with a higher quality health service experience while injecting new vitality into the entire healthcare industry."

Dai Wenhao said, "This strategic cooperation with Shanghai Cell Therapy Group is not only a choice for complementary advantages and win-win cooperation between the two parties, but also a vivid practice of implementing the 'Healthy China' strategy and serving the people's better life. We look forward to taking this signing as an opportunity to jointly create a new ecosystem of 'insurance + health services' and bring customers more cutting-edge health security solutions."

Both parties unanimously believe that the conclusion of this strategic cooperation marks a solid step forward in their collaboration within the health services and insurance sectors. This will not only bring new development opportunities for both parties but also inject fresh vitality into the entire healthcare industry.

Empower health with technology, and warm lives with service. Shanghai Cell Therapy Group and Aeon Life Insurance Company Limited will continue to deepen their cooperation, jointly exploring innovative models of cell therapy and insurance services, to provide customers with a more comprehensive and cutting-edge health security system.

Haier Capital will empower co-creators based on the full ecological model of the industry, promote the expansion of industrial boundaries among ecosystem partners, and jointly build a sustainable, secure, and stable medical ecosystem that meets the needs of the country. Together with co-creators, it will contribute to the realization of the grand blueprint of "Healthy China."